METHODS AND COMPOSITIONS RELATED TO NK CELL AND ANTI-PDL1 CANCER THERAPIES

• US 20190309070A1
• Filed: 10/05/2017
• Published: 10/10/2019
• Est. Priority Date: 10/05/2016
• Status: Active Application

• Current Assignee: University of Central Florida Research Foundation Inc. (State University System of Florida)
• Original Assignee: University of Central Florida Research Foundation Inc. (State University System of Florida)
• Inventors: Copik, Alicja J., Igarashi, Robert Y., Oyer, Jeremiah J., Altomare, Deborah A.
• Application Number:
  US16/339,781
• Publication Number:
  US 20190309070A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2239/59 Reproductive system, e.g. uterus, ovaries, cervix or testes
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 38/208 IL-12
• CPC Class Codes: A61K 38/2086 IL-13 to IL-16
• CPC Class Codes: A61K 39/4613 Natural-killer cells [NK or NK-T]
• CPC Class Codes: A61K 39/4621 immunosuppressive or immunotolerising
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C12N 2501/51 B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
• CPC Class Codes: C12N 5/0646 Natural killers cells [NK], NKT cells

Abstract

Disclosed are compositions and methods relating to the treatment of a cancer via the induction of PDL1 and use of anti-PDL1 antibodies.

Claims

1. A method of treating a cancer in a subject comprising administering to the subject NK cells and an anti-PDL1 antibody.

2. The method of claim 1, wherein the NK cells are XM NK cells.

3. The method of claim 1, wherein the NK cells are activated or expanded by contacting a naive NK cell population with PM21 particles, EX21 exosomes, or FC21 feeder cells.

4. The method of claim 3, wherein the activation or expansion of NK cells by PM21 particles, EX21 exosomes, or FC21 cells occurs ex vivo.

5. The method of claim 4, wherein the activation of expansion of NK cells by PM21 particles, EX21 exosomes, or FC21 cells occurs between 1 and 21 days prior to the administration of the NK cells to the subject.

8. The method of treating cancer of claim 1, wherein the NK cells are administered between 1 and 14 days prior to administration of the anti-PDL1 antibody.

9. The method of treating cancer of claim 1, wherein the NK cells and anti-PDL1 antibody are administered concurrently.

11. The method of treating cancer of claim 1, further comprising contacting the NK cells with one or more of IL-12, IL-15, and IL-18 prior to administration of the NK cells to the subject.

12. The method of treating cancer of claim 1, further comprising administering to the subject one or more of IL-12, IL-15, and IL-18.

13. The method of treating cancer of claim 12, wherein the IL-12, IL-15, and IL-18 are administered concurrently with, prior to, or following the administration of the NK cells.

16. The method of treating cancer of claim 1, further comprising administering PM21 particles or EX21 exosomes to the subject.

18. The method of treating cancer of claim 16, wherein the PM21 particles or EX21 exosomes are administered at least 1, 2, 3 times per week following the administration of the NK cells.

6. (canceled)

7. (canceled)

10. (canceled)

14. (canceled)

15. (canceled)

17. (canceled)

19. A method of treating a cancer in a subject comprising administering to the subject PM21 particles or EX21 exosomes and an anti-PDL1 antibody.

20. The method of treating cancer of claim 19, wherein the PM21 particles or EX21 exosomes are administered between 1 and 14 days prior to administration of the anti-PDL1 antibody.

21. The method of treating cancer of claim 19, wherein the PM21 particles or EX21 exosomes and the anti-PDL1 antibody are administered concurrently.

22. The method of treating cancer of claim 19, further comprising administering one or more of IL-12, IL-15, and IL-18.

23. The method of treating cancer of claim 22, wherein the IL-12, IL-15, and IL-18 are administered concurrently with, prior to, or following the administration of the PM21 particles or EX21 exosomes.

26. The method of treating cancer of claim 19, wherein the PM21 particles or EX21 exosomes are administered at least 1, 2, 3 times per week following the initial administration of PM21 particles or EX21 exosomes.

24. (canceled)

25. (canceled)

27. An anti-cancer therapy comprising PM21, EX21, or FC21 NK cells and an anti-PDL1 antibody

29. The anti-cancer therapy of claim 27, further comprising one or more of IL-12, IL-15, and IL-18.

28. (canceled)

30. (canceled)

31. (canceled)